Posted by Michael Wonder on 20 Aug 2022
Fresenius Kabi announces acceptance of its marketing authorisation application by the European Medicines Agency for MSB11456, a tocilizumab biosimilar candidate
18 August 2022 - Fresenius Kabi announced today that its marketing authorisation application for MSB11456, the company’s tocilizumab biosimilar candidate, has been accepted for review by the EMA.
Fresenius Kabi’s submission for its tocilizumab biosimilar candidate of RoActemra includes comprehensive analytical, non-clinical and clinical similarity data.
